岩舒注射液联合NP方案治疗晚期非小细胞肺癌的系统评价

Systematic review on Yanshu injection plus NP for terminal NSCLC

目的:评价岩舒注射液联合NP方案化疗与单纯NP方案化疗(干预Ⅰ与干预Ⅱ)治疗晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法:采用Cochrane系统评价方法,计算机检索Medline、CBM、CNKI、VIP、万方数据库和Cochrane图书馆临床对照试验库等,对纳入的同质研究采用RevMan 5.0进行Meta分析。结果:Meta分析结果表明,干预Ⅰ在提高近期疗效有效率、生存质量、疼痛缓解率及部分化疗毒副反应改善率方面均优于干预Ⅱ,差异有统计学意义,P<0.05。结论:岩舒注射液对晚期NSCLC有一定的治疗作用,但鉴于纳入试验的方法学质量普遍较低,期待更多设计合理、严格执行的大样本随机对照双盲试验提供较高质量的临床证据。

OBJECTIVE： To make a systematic review on effectiveness and safety of Yanshu injection plus NP chemotherapy compared to NP alone （Therapy I versus Therapy II ） for terminal non-small cell lung cancer （NSCLC）. METHODS： Medline, CBM, CNKI, VIP, Wanfangdata and the Cochrane Library were searched. The quality of included studies was assessed according to the Cochrane library, and Meta-analysis were performed by RevMan 5.0 software. RESULTS： The results showed that Therapy I , compared with Therapy II , could significantly improve the tumor response and the quality of life, reduce the pain and some toxicities （P〈 0.05）. CONCLUSIONS： Therapy I is more therapeutically beneficial. However, considering the strength of the evidence, additional randomized controlled doubleblinded trials with higher quality are needed before Therapy I can be recommended routinely.